A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995, IND 61,198), in Combination With 13-Cis-Retinoic Acid in Metastatic Progressive Cancer.
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2016
At a glance
- Drugs Entinostat (Primary) ; Isotretinoin (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 31 Mar 2008 Status change from in progress to completed, as reported by clinicaltrials.gov.
- 08 Aug 2005 New trial record.